Evidence map›Paper›PMID 41469380›Full record

ArticleNature communications2025

Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1

Louise Gorline, Fillipe Luiz Rosa do Carmo, Pierre Bourdely, Jérémie Bornères, Nathan Vaudiau, Aurélie Semervil, Mathias Vetillard, Aboubacar Sidiki K Coulibaly, Natacha Jugniot, Agathe Ok and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Louise Gorline *Dendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France.ORCID http://orcid.org/0009-0008-8499-9603
Fillipe Luiz Rosa do Carmo *Dendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France.
Pierre BourdelyLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4162-1490
Jérémie BornèresDendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France.
Nathan VaudiauDendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France.ORCID http://orcid.org/0000-0001-9586-8467
Aurélie SemervilDendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France.ORCID http://orcid.org/0009-0000-6595-3441
Mathias VetillardBichat Medical School, INSERM UMR1149, CNRS EMR8252, Université Paris Cité, Paris, France.
Aboubacar Sidiki K CoulibalyDendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France.
Natacha JugniotDendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France.
Agathe OkBichat Medical School, INSERM UMR1149, CNRS EMR8252, Université Paris Cité, Paris, France.ORCID http://orcid.org/0009-0005-9883-5288
Mathilde BausartDepartment of Pathology and Immunology, Geneva Medical School, Geneva, Switzerland.
Oriane FiquetHuman Disease Models Core Facility, Institut Pasteur, Université Paris Cité, Paris, France.
Marine AndradeHuman Disease Models Core Facility, Institut Pasteur, Université Paris Cité, Paris, France.
Dicken FardolNutrition and Obesity: Systemic Approaches, Inserm, Sorbonne University, Paris, France.ORCID http://orcid.org/0009-0005-6487-0704
Ikrame HaddarDendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France.
Zeina Abou NaderINSERM UMR 1016, CNRS UMR 8104, Institut Cochin, Université Paris Cité, Paris, France.
Judith WeberINSERM UMR 1016, CNRS UMR 8104, Institut Cochin, Université Paris Cité, Paris, France.ORCID http://orcid.org/0009-0001-5349-162X
Hannah TheobaldInserm U1015, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Matthieu CollinInserm Transfert, Paris, France.
Joseph CalmetteInserm Transfert, Paris, France.
Giorgio AnselmiDeparment of Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.ORCID http://orcid.org/0000-0002-8870-3354
Flavia FicoDepartment of Pathology and Immunology, Geneva Medical School, Geneva, Switzerland.
Florent GinhouxInserm U1015, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.ORCID http://orcid.org/0000-0002-2857-7755
Laleh MajlessiVirology Department, Pasteur-TheraVectys Joint Laboratory, Institut Pasteur, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0001-8648-4058
Emmanuel L GautierNutrition and Obesity: Systemic Approaches, Inserm, Sorbonne University, Paris, France.
Loredana SaveanuBichat Medical School, INSERM UMR1149, CNRS EMR8252, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0003-3138-7968
Julie HelftINSERM UMR 1016, CNRS UMR 8104, Institut Cochin, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-2733-1972
Marc DalodCentre d'Immunologie de Marseille-Luminy, CIML, CNRS, INSERM, Aix Marseille Université, Marseille, France.ORCID http://orcid.org/0000-0002-6436-7966
Mathilde DusseauxHuman Disease Models Core Facility, Institut Pasteur, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0003-0131-3853
James P Di SantoCentre for Vaccine and Immunotherapy, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0002-7146-1862
Stéphanie HuguesDepartment of Pathology and Immunology, Geneva Medical School, Geneva, Switzerland.
Pierre GuermonprezDendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France. pierre.guermonprez@pasteur.fr.ORCID http://orcid.org/0000-0001-5621-2262

Funding

Institut National Du Cancer (French National Cancer Institute) PL-BIO22-147
6 · The paper itself

Abstract

Tumor infiltration by XCR1⁺ conventional dendritic cells (cDC1) correlates strongly with favorable prognosis and improved responses to immunotherapy. Yet, tumor-driven immunosuppressive programs restrict efficient cDC1 recruitment, highlighting the need for strategies to increase cDC1 access to the tumor microenvironment. Here, we establish a proof-of-concept cell-based immunotherapy that enhances the infiltration of circulating cDC1 progenitors and supports their local expansion. Intratumoral engraftment of autologous mesenchymal stromal cells engineered to express membrane bound FLT3L promotes cDC1 recruitment when combined with poly(I:C). We identify poly(I:C)-induced CXCL9 and CCL5 as essential chemokines controlling intratumoral cDC1 infiltration. Stromal cell-mediated local delivery of FLT3L together with CXCL9 and CCL5 is sufficient to enhance cDC1 infiltration in mice or humanized mice settings. Finally, this approach activates antitumor immunity and partially overcomes resistance to immune checkpoint blockade. Collectively, our data support the therapeutic potential of expanding intratumoral cDC1s through local and sustained delivery of FLT3L, CXCL9, and CCL5.

Indexed as

Dendritic CellsMembrane ProteinsNeoplasmsReceptors, CCR5Receptors, CXCR3AnimalsCell Line, TumorChemokine CCL5Chemokine CXCL9FemaleHumansImmunotherapyLigandsMesenchymal Stem CellsMiceReceptors, G-Protein-CoupledCCR5 protein, humanChemokine CCL5Chemokine CXCL9CXCR3 protein, humanflt3 ligand proteinLigandsMembrane ProteinsReceptors, CCR5Receptors, CXCR3Receptors, G-Protein-CoupledXCR1 protein, human

Identifiers

PMID41469380
PMCPMC12865026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.